<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "cyclophosphamide inj VIAL">
<dose><value>1000</value>
<value>500</value>
<value>700</value>
<value>600</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>cyclophosphamide inj VIAL</value>
</drugname><strength><value>1000 mg</value>
<value>2000 mg</value>
<value>500 mg</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>DAY 1 of 21. Administer dose diluted in 100 to 250 mL - 0.9%25 sodium chloride over 30 minutes.</value>
<value>DAY 1 of 21. Administer dose diluted in 100 mL 0.9%25 sodium chloride over 15 to 60 minutes. (May start administration during post-hydration.)</value>
<value>DAY 4 of 21. Administer dose diluted in 100 mL 0.9%25 sodium chloride over 20 to 30 minutes.</value>
<value>DAY 1 of 21. Administer dose diluted in 100 mL 0.9%25 sodium chloride over 15 to 60 minutes.</value>
</instruction><volume></volume><units><value>mg/m2</value>
</units><additionalnotes><value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. If Creatinine Clearance is greater than or equal to 50 mL/minute: Give as ordered. If Creatinine Clearance is less than 50 mL/minute: Contact physician.</value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week.</value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. [Part 1: Cycles 1, 2, 3, &amp; 4] </value>
</additionalnotes><population><value>cyclophosphamide, DOXOrubicin, vinCRIStine (CAV). Small Cell Lung Cancer.</value>
<value>DOXOrubicin/CISplatin/cyclophosphamide (PAC). Thymic Malignancy</value>
<value>CISplatin/DOXOrubicin/vinCRIStine/cyclophosphamide. Thymoma</value>
<value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel &amp; Trastuzumab</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by DOCEtaxel. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by DOCEtaxel and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by PACLitaxel (weekly) and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3360</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3361</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3359</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02241799</value>
<value>02241800</value>
<value>02241798</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>